跳至主要内容
MedPath Trial logoMedPath TrialMedPath Trial Home
临床试验/NCT06504225
NCT06504225招募中不适用

Long-term Evaluation of the Value of Using an MTor Inhibitor (everolimus) for the Minimisation of Anticalceurins in Old-for-old Kidney Transplantation

University Hospital, Brest14 个研究点 分布在 1 个国家目标入组 260 人开始时间: 2024年8月23日最近更新:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
适应症

试验速览

阶段
不适用
状态
招募中
入组人数
260
试验地点
14
主要终点
Patient survival
研究概览研究设计入排标准结局指标研究者研究点记录与标识符相似试验

研究概览

简要总结

Long Term Follow up of EVEROLD study

研究设计

研究类型
Observational
观察模型
Case Only
时间视角
Retrospective

入排标准

年龄范围
18 Years 至 —（Adult, Older Adult）
性别
All
接受健康志愿者
否

入选标准

  • •Informed patients participating to the EVEROLD study
  • •Patient having completed the EVEROLD M12 follow-up visit
  • •Patient agreeing to participate in the observational study

排除标准

  • •Opposition to the use his medical data
  • •Patient under legal protection

结局指标

主要结局

Patient survival

时间窗: up to 12 years

Patient survival at last follow-up

Graft survival

时间窗: up to 12 years

Graft survival at last follow-up

次要结局

  • Major cardiovascular events(up to 12 years)
  • Rejection rate(up to 12 years)
  • Infection rate(up to 12 years)
  • Hospitalization(up to 12 years)
  • eGFR(up to 12 years)
  • Cancer rate(up to 12 years)

研究者

申办方类型
Other
责任方
Sponsor

研究点 (14)

Loading locations...

相似试验

终止
3 期
A Follow-up Study of Rotigotine Patch in Adolescent Subjects With Restless Legs SyndromeRestless Legs Syndrome
NCT03992196UCB Biopharma SRL10
进行中（未招募）
3 期
A Long-term Follow-up Study of Sotatercept for PAH Treatment (MK-7962-004/A011-12)Pulmonary Arterial HypertensionPAH
NCT04796337Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA815
进行中（未招募）
1 期
ong-Term Safety and Efficacy Evaluation of amlitelimab in adult participants with moderate to severe atopic dermatitis.
EUCTR2021-002344-73-DESanofi-aventis recherche & développement315
进行中（未招募）
1 期
ong-Term Safety and Efficacy Evaluation of amlitelimab in adult participants with moderate to severe atopic dermatitis.
EUCTR2021-002344-73-HUSanofi-aventis recherche & développement315
进行中（未招募）
1 期
ong-Term Safety and Efficacy Evaluation of amlitelimab in adult participants with moderate to severe atopic dermatitis.Dermatitis atopicMedDRA version: 20.0Level: PTClassification code 10012438Term: Dermatitis atopicSystem Organ Class: 10040785 - Skin and subcutaneous tissue disorders
EUCTR2021-002344-73-CZSanofi-aventis recherche & développement315